Your session is about to expire
← Back to Search
Carfilzomib + Lenalidomide + Dexamethasone for Multiple Myeloma
Study Summary
This trial is studying a combination of three drugs as a possible treatment for smoldering multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 126 Patients • NCT03029234Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I have a GI condition that affects my body's ability to absorb medications.I do not have severe nerve pain or damage.You are currently taking any other experimental medications.You had another type of cancer in the past, but it has been 2 years since you had treatment and you are not currently having any symptoms.I have not had major surgery in the last month.My condition is confirmed as Smoldering Multiple Myeloma by a recognized lab.My blood pressure or diabetes is not well-managed.I have serious heart issues, including recent heart attacks or unstable heart conditions.I do not have an active hepatitis B or C infection.I can take care of myself but might not be able to do heavy physical work.I agree to use birth control during the study.I am allergic to medications similar to carfilzomib or lenalidomide.I have high-risk Smoldering Multiple Myeloma.I have not had any treatments for SMM in the last 4 weeks.You have a measurable disease according to specific guidelines within the past 4 weeks.I do not have any severe illnesses or social situations that would prevent me from following the study's requirements.I am allergic or react badly to certain medications.I have been diagnosed with multiple myeloma.My organ and bone marrow functions are normal.
- Group 1: Group A - (closed) - Carfilzomib with Revlimid and Dexamethasone
- Group 2: Group B - Carfilzomib with Revlimid and Dexamethasone
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Carfilzomib been granted regulatory approval by the Food and Drug Administration?
"Carfilzomib has not yet been verified to be efficacious, but there is some evidence of its safety and so it was assigned a rating of 2."
How many participants are enrolled in this medical research experiment?
"Alas, no longer is this clinical trial recruiting participants. Initially posted on May 29th 2012 and last updated on August 17th 2022, the study has since ceased its search for volunteers. However, there are 808 trials searching for individuals with multiple myeloma and 704 studies looking to recruit people taking Carfilzomib."
Have any other experiments been carried out regarding the use of Carfilzomib?
"Presently, 704 medical trials are researching the effects of Carfilzomib. Of those studies, 167 have entered Phase 3 testing. While Mishawaka, Indiana is a hub for research on this medication, there are over 25 thousand other sites running tests all across the world."
What clinical indications is Carfilzomib most regularly employed to address?
"Carfilzomib is typically used to manage ophthalmia and sympathetic conditions, but can also be a viable intervention for other diseases such as branch retinal vein occlusion and macular edema in patients that have already received two systemic chemotherapies."
Is this clinical investigation currently accepting participants?
"Recruitment for this medical trial has concluded; its initial posting occured on May 29th 2012, with the latest edit taking place on August 17th 2022. For those exploring other studies, there are 808 active clinical trials looking for individuals with multiple myeloma and 704 featuring Carfilzomib as their intervention of choice."
To what end is this clinical trial striving?
"This 8-month long clinical trial aims to measure Response Rate as its primary outcome, with other secondary objectives being the assessment of adverse events via CTCAE v4.0, MRDnegative Complete Responses persisting for a minimum of 1 year and Clinical Progression Free Survival from enrolment until development of overt multiple myeloma or death."
Share this study with friends
Copy Link
Messenger